MedTrace Logo

Swiss Multiple Sclerosis Cohort-Study

NCT02433028 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1200

Last updated 2025-04-14

No results posted yet for this study

Summary

The Swiss MS Cohort Study (SMSC) is a multicentre cohort study that involves 8 Swiss Multiple Sclerosis centres. The key aims of the SMSC are

1. To maintain a long-term cohort for an undefined duration of patients with Multiple Sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD) and Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in Switzerland. This requires effective measures to limit drop-outs and the continuous recruitment of MS patients and
2. To conduct a systematic follow-up with standardized, high quality collection of clinical and magnetic resonance imaging (MRI) data, as well as body fluids.

The significant heterogeneity within the diagnostic entity and phenotype of MS is incompletely understood. A central and necessary prerequisite of further advance is a sufficient amount of high quality clinical and paraclinical (imaging, body fluids) patient data.

Nested projects will address specific research topics, and facilitate collaboration of the most qualified investigators within the group of SMSC investigators. The nested projects will focus on the:

1. Development and validation of diagnostic and prognostic markers of spontaneous disease evolution and therapeutic response.
2. Exploration of the safety and impact on long-term disability of existing and next generation MS treatments
3. Individualized therapy: A number of highly active but potentially also harmful therapies have lately been established for the treatment of MS. To date, due to the lack of individual prognostic markers patients may not receive aggressive therapy due to safety concerns, or patients with benign disease may receive expensive and potentially harmful treatments without the need for it.
4. Evaluation of intervention effects by conducting embedded pragmatic trials using the SMSC as data-infrastructure.

Conditions

Sponsors & Collaborators

  • Cantonal Hospital of Aarau, Switzerland

    collaborator OTHER

  • Cantonal Hospital of St. Gallen

    collaborator OTHER

  • Insel Gruppe AG, University Hospital Bern

    collaborator OTHER

  • Regional Hospital Lugano (EOC), Switzerland

    collaborator UNKNOWN

  • University Hospital, Geneva

    collaborator OTHER

  • University of Lausanne Hospitals

    collaborator OTHER

  • National Multiple Sclerosis Society

    collaborator OTHER

  • University Hospital, Basel, Switzerland

    lead OTHER

Principal Investigators

  • Jens Kuhle, MD · University Hospital, Basel, Switzerland

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-06-30
Primary Completion
2042-01-31
Completion
2042-01-31

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02433028 on ClinicalTrials.gov